Specify a stock or a cryptocurrency in the search bar to get a summary
ConvaTec Group PLC
2CVConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other causes, as well as critical care devices and products used in intensive care units and hospital settings. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom. Address: 20 Eastbourne Terrace, London, United Kingdom, W2 6LG
Analytics
WallStreet Target Price
211.83 GBXP/E ratio
39.0667Dividend Yield
2.1 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 2CV
Dividend Analytics 2CV
Dividend growth over 5 years
9 %Continuous growth
3 yearsPayout Ratio 5 years average
330 %Dividend History 2CV
Stock Valuation 2CV
Financials 2CV
Results | 2019 | Dynamics |